{
    "clinical_study": {
        "@rank": "97588", 
        "acronym": "SITRR", 
        "biospec_descr": {
            "textblock": "-  Three blood samples are going to be conserved : one during the week before the\n           operation, one four to eight weeks next to the operation and the last one, at the\n           relapse.\n\n        -  Biopsie of non small cell lung cancer will be conserved too."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Description of new transcriptional profiles associated with risk of relapse and\n      identification of specific sites of relapse in non-small cell lung cancer, toxicity and\n      resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer\n      (NSCLC)."
        }, 
        "brief_title": "Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  A first blood sample will be taken during the week before the operation. A second blood\n           sample will be taken 4 to 8 weeks after the operation. And in case of relapse, a third\n           sample will be taken. These samples are going to be stored in the collection of\n           biological resources of Angers.\n\n        -  Concerning the biopsy of the resected NSLCL, it will be sent to the collection of\n           biological resources of Angers for conservation directly next to the surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Major subject\n\n          -  Subject who received resection with primary non-small cell lung cancer at the\n             University Hospital of Angers and whose tumor samples will be stored in collection of\n             biological resources of University Hospital of Angers\n\n          -  A written inform consent.\n\n        Exclusion Criteria:\n\n          -  Under 18 year old;\n\n          -  Pregnant or nursing women;\n\n          -  Deprived of liberty;\n\n          -  Age under curatorship or guardianship;\n\n          -  Unable to consent person;\n\n          -  About not carrying a non-small cell lung cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with non small cell lung cancer"
            }
        }, 
        "enrollment": {
            "#text": "192", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075957", 
            "org_study_id": "2012-A00827-36"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Non-small cell lung cancer, adjuvant chemo-therapy, DNA chip", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "contact": {
                "email": "johureaux@chu-angers.fr", 
                "last_name": "Jos\u00e9 HUREAUX, Doctor", 
                "phone": "2 41 35 36 78", 
                "phone_ext": "+33"
            }, 
            "contact_backup": {
                "email": "amandine.aulnette@chu-angers.fr", 
                "last_name": "Amandine AULNETTE, CRA", 
                "phone": "2 41 35 80 15", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Angers", 
                    "country": "France", 
                    "state": "Maine et Loire", 
                    "zip": "49933"
                }, 
                "name": "UH Angers"
            }, 
            "investigator": [
                {
                    "last_name": "Jos\u00e9 HUREAUX, Doctor", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Thierry URBAN, Professor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Thierry JEANFAIVRE, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nathalie BAIZE, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gonzague DE CHABOT, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "C\u00e9cile RIEUX, Doctor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer", 
        "overall_contact": {
            "email": "johureaux@chu-angers.fr", 
            "last_name": "Jos\u00e9 HUREAUX, Doctor", 
            "phone": "241353678", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "amandine.aulnette@chu-angers.fr", 
            "last_name": "Amandine AULNETTE, CRA", 
            "phone": "241358015", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Angers", 
            "last_name": "Jos\u00e9 HUREAUX, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "6 to 8 weeks after surgery"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 1 year"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 2 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 3 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 4 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 5 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 6 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 7 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 8 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 9 years"
            }, 
            {
                "description": "The news microarrays profiles of NSCLC relapse risks will :\nassessing the risk of relapse in patients undergoing resection of NSCLC (by knowing this risk, patients at highest risk of relapse would be treated as a priority, while avoiding treating patients with low risk)\nassessing the risk of chemo-resistant tumor cells characters to optimize the choice of treatment to offer to the patient\nassessing the prediction of sites most likely metastatic relapse to guide survey strategy.", 
                "measure": "Determination of news microarrays profiles of NSCLC relapse risks", 
                "safety_issue": "Yes", 
                "time_frame": "At 10 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075957"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Hospital, Angers", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Angers", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}